Evidence map›Paper›PMID 26879230›Full record

ArticleCirculation research2016

Selective Targeting of a Novel Epsin-VEGFR2 Interaction Promotes VEGF-Mediated Angiogenesis.

H N Ashiqur Rahman, Hao Wu, Yunzhou Dong, Satish Pasula, Aiyun Wen, Ye Sun, Megan L Brophy, Kandice L Tessneer, Xiaofeng Cai, John McManus and 10 more

Abstract read
In one paragraph

Article in Circulation research, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed
2.6field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed, 45 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Review
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Epsins in vascular development, function and disease.Cellular and molecular life sciences : CMLS · 2021
    Review
  15. Article
  16. Periosteum Mimetic Coating on Structural Bone AllograftsACS biomaterials science & engineering · 2020
    Article
  17. Article
  18. Endocytic Adaptors in Cardiovascular Disease.Frontiers in cell and developmental biology · 2020
    Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 1 institution in 1 country.

H N Ashiqur Rahman *Vascular Biology Program, Karp Family Research Labs #12.214, Harvard Medical School, Boston Children's Hospital, 300 Longwood Ave, Boston, MA 02115, USA.
Hao Wu *Vascular Biology Program, Karp Family Research Labs #12.214, Harvard Medical School, Boston Children's Hospital, 300 Longwood Ave, Boston, MA 02115, USA.
Yunzhou Dong *Vascular Biology Program, Karp Family Research Labs #12.214, Harvard Medical School, Boston Children's Hospital, 300 Longwood Ave, Boston, MA 02115, USA.
Satish PasulaCardiovascular Biology Program, Oklahoma Medical Research Foundation, Oklahoma, OK 73104, USA.
Aiyun WenVascular Biology Program, Karp Family Research Labs #12.214, Harvard Medical School, Boston Children's Hospital, 300 Longwood Ave, Boston, MA 02115, USA.
Ye SunVascular Biology Program, Karp Family Research Labs #12.214, Harvard Medical School, Boston Children's Hospital, 300 Longwood Ave, Boston, MA 02115, USA.
Megan L BrophyVascular Biology Program, Karp Family Research Labs #12.214, Harvard Medical School, Boston Children's Hospital, 300 Longwood Ave, Boston, MA 02115, USA.
Kandice L TessneerCardiovascular Biology Program, Oklahoma Medical Research Foundation, Oklahoma, OK 73104, USA.
Xiaofeng CaiVascular Biology Program, Karp Family Research Labs #12.214, Harvard Medical School, Boston Children's Hospital, 300 Longwood Ave, Boston, MA 02115, USA.
John McManusCardiovascular Biology Program, Oklahoma Medical Research Foundation, Oklahoma, OK 73104, USA.
Baojun ChangCardiovascular Biology Program, Oklahoma Medical Research Foundation, Oklahoma, OK 73104, USA.
Sukyoung KwakVascular Biology Program, Karp Family Research Labs #12.214, Harvard Medical School, Boston Children's Hospital, 300 Longwood Ave, Boston, MA 02115, USA.
Negar S RahmanCardiovascular Biology Program, Oklahoma Medical Research Foundation, Oklahoma, OK 73104, USA.
Wenjia XuCardiovascular Biology Program, Oklahoma Medical Research Foundation, Oklahoma, OK 73104, USA.
Conrad FernandesCardiovascular Biology Program, Oklahoma Medical Research Foundation, Oklahoma, OK 73104, USA.
John Michael McdanielCardiovascular Biology Program, Oklahoma Medical Research Foundation, Oklahoma, OK 73104, USA.
Lijun XiaCardiovascular Biology Program, Oklahoma Medical Research Foundation, Oklahoma, OK 73104, USA.
Lois SmithVascular Biology Program, Karp Family Research Labs #12.214, Harvard Medical School, Boston Children's Hospital, 300 Longwood Ave, Boston, MA 02115, USA.
R Sathish SrinivasanCardiovascular Biology Program, Oklahoma Medical Research Foundation, Oklahoma, OK 73104, USA.
Hong ChenVascular Biology Program, Karp Family Research Labs #12.214, Harvard Medical School, Boston Children's Hospital, 300 Longwood Ave, Boston, MA 02115, USA.
Oklahoma Medical Research Foundation · US

Funding

Protein-glycan Interactions in the Vascular SystemP01HL085607 · NHLBI · OKLAHOMA MEDICAL RESEARCH FOUNDATION · PI MCEVER, RODGER PAUL · 2006 to 2015
$16.8M
SWI/SNF-REGULATED POSTNATAL ANGIOGENESISP20RR018758 · NCRR · OKLAHOMA MEDICAL RESEARCH FOUNDATION · PI MCEVER, RODGER PAUL · 2003 to 2011
$14.9M
Dietary control of angiogenesis in retinopathy modelsR01EY017017 · NEI · BOSTON CHILDREN'S HOSPITAL · PI Zhongjie Fu, Lois Smith · 2006 to 2026
$11.8M
Epsin in Angiogenesis and Vascular RemodelingR01HL093242 · NHLBI · OKLAHOMA MEDICAL RESEARCH FOUNDATION · PI CHEN, HONG, WANG, DA-ZHI · 2009 to 2021
$7.3M
Mouse Neurodevelopmental Behavior CoreU54HD090255 · NICHD · BOSTON CHILDREN'S HOSPITAL · PI POMEROY, SCOTT LOREN · 2016 to 2020
$5.2M
Mechanisms regulating VEGF receptors in diabetic angiogenesisR01HL130845 · NHLBI · BOSTON CHILDREN'S HOSPITAL · PI CHEN, HONG, XU, JIAN · 2016 to 2023
$4.9M
Molecular Mechanisms Regulating Endothelial DysfunctionR01HL137229 · NHLBI · BOSTON CHILDREN'S HOSPITAL · PI CHEN, HONG, SRIVASTAVA, SANJAY · 2017 to 2020
$2.7M
The Role of Signaling Adaptor Protein Epsin in AtherosclerosisR01HL118676 · NHLBI · OKLAHOMA MEDICAL RESEARCH FOUNDATION · PI CHEN, HONG · 2014 to 2017
$1.8M
Molecular Mechanisms Regulating Epsin-Dependent LRP-1 Internalization and Degradation in AtherosclerosisF31HL127982 · NHLBI · UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR · PI BROPHY, MEGAN · 2015 to 2017
$101k
A Novel Role for Endothelial Epsins in TNF signaling, Inflammation, and AtherosclF32HL121954 · NHLBI · OKLAHOMA MEDICAL RESEARCH FOUNDATION · PI TESSNEER, KANDICE LYNN · 2014 to 2014
$30k
NCRR NIH HHS P20 RR018758NEI NIH HHS R01 EY017017NHLBI NIH HHS 1F31HL127982-01NHLBI NIH HHS 1F32HL121954-01NHLBI NIH HHS F31 HL127982NHLBI NIH HHS F32 HL121954NHLBI NIH HHS P01 HL085607NHLBI NIH HHS R01 HL093242NHLBI NIH HHS R01HL-093242NHLBI NIH HHS R01 HL118676NHLBI NIH HHS R01HL-118676NHLBI NIH HHS R01 HL130845NHLBI NIH HHS R01HL-130845NHLBI NIH HHS R01 HL137229NICHD NIH HHS U54 HD090255
6 · The paper itself

Abstract

rationaleWe previously reported that vascular endothelial growth factor (VEGF)-induced binding of VEGF receptor 2 (VEGFR2) to epsins 1 and 2 triggers VEGFR2 degradation and attenuates VEGF signaling. The epsin ubiquitin interacting motif (UIM) was shown to be required for the interaction with VEGFR2. However, the molecular determinants that govern how epsin specifically interacts with and regulates VEGFR2 were unknown.

objectiveThe goals for the present study were as follows: (1) to identify critical molecular determinants that drive the specificity of the epsin and VEGFR2 interaction and (2) to ascertain whether such determinants were critical for physiological angiogenesis in vivo. METHODS AND

resultsStructural modeling uncovered 2 novel binding surfaces within VEGFR2 that mediate specific interactions with epsin UIM. Three glutamic acid residues in epsin UIM were found to interact with residues in VEGFR2. Furthermore, we found that the VEGF-induced VEGFR2-epsin interaction promoted casitas B-lineage lymphoma-mediated ubiquitination of epsin, and uncovered a previously unappreciated ubiquitin-binding surface within VEGFR2. Mutational analysis revealed that the VEGFR2-epsin interaction is supported by VEGFR2 interacting specifically with the UIM and with ubiquitinated epsin. An epsin UIM peptide, but not a mutant UIM peptide, potentiated endothelial cell proliferation, migration and angiogenic properties in vitro, increased postnatal retinal angiogenesis, and enhanced VEGF-induced physiological angiogenesis and wound healing.

conclusionsDistinct residues in the epsin UIM and VEGFR2 mediate specific interactions between epsin and VEGFR2, in addition to UIM recognition of ubiquitin moieties on VEGFR2. These novel interactions are critical for pathophysiological angiogenesis, suggesting that these sites could be selectively targeted by therapeutics to modulate angiogenesis.

Indexed as

Adaptor Proteins, Vesicular TransportAmino Acid SequenceAnimalsDrug Delivery SystemsHEK293 CellsHumansHuman Umbilical Vein Endothelial CellsMCF-7 CellsMiceMice, Inbred C57BLMice, KnockoutMice, TransgenicMolecular Sequence DataNeovascularization, PhysiologicProtein BindingProtein Structure, SecondaryAdaptor Proteins, Vesicular TransportepsinKDR protein, humanVascular Endothelial Growth Factor AVascular Endothelial Growth Factor Receptor-2VEGFA protein, humanepsinneovascularization, physiologicubiquitinubiquitinationVEGFR2 protein, mouse

Identifiers

PMID26879230
PMCPMC4798882
OpenAlexW2282205760

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.